Protagenic Therapeutics, Inc.\new (PTIX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 03-31. Amounts in USD.

Revenue Quarterly

0 5M 10M 15M Q1 '11: 10.8M Q2 '11: 9.2M Q1 '12: 6.3M Q2 '12: 12.3M Q4 '15: 0 Q1 '16: 0 Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q2 '21: 0 Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 0 Q4 '22: 0 Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q1 '26: 0 Q2 '26: 0 Q3 '26: 0 Q4 '26: 0 Q1 '12 Q3 '16 Q4 '17 Q4 '21 Q1 '23 Q2 '24 Q3 '25 Q4 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-1.8M -1.2M -600K 0 600K 1.2M 1.8M Q2 '17: -454.8K Q3 '17: -556.3K Q4 '17: -657.9K Q1 '18: -471.6K Q2 '18: -527K Q3 '18: -708.8K Q4 '18: -606.7K Q1 '19: -685.1K Q2 '19: -498.1K Q3 '19: -524.2K Q4 '19: -654K Q1 '20: -505.3K Q2 '20: -189.6K Q3 '20: -737.2K Q4 '20: -520.7K Q1 '21: -488.9K Q2 '21: -1.1M Q3 '21: -536.9K Q4 '21: -1.2M Q1 '22: -1.3M Q2 '22: -764.2K Q3 '22: -861.2K Q4 '22: -1.3M Q1 '23: -636.7K Q2 '23: -924.1K Q3 '23: -655.8K Q4 '23: -739.3K Q1 '24: -1.1M Q2 '24: -1.4M Q3 '24: -1.2M Q4 '24: -1.7M Q1 '25: -321.8K Q2 '25: -355.4K Q3 '25: -401.4K Q4 '25: -1.4M Q1 '26: -1.2M Q2 '26: -1.1M Q3 '26: -925.1K Q4 '26: -120.3K Q1 '27: -961.2K Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q2 '23 Q3 '24 Q4 '25 Q1 '27

Net Income Quarterly

-6M -4M -2M 0 2M 4M 6M Q2 '17: -455.5K Q3 '17: -556.1K Q4 '17: -657.9K Q1 '18: -451.1K Q2 '18: -454.6K Q3 '18: -696.1K Q4 '18: -598.2K Q1 '19: -672.2K Q2 '19: -497.5K Q3 '19: -789.7K Q4 '19: -599.2K Q1 '20: -278.5K Q2 '20: -123.3K Q3 '20: -749.9K Q4 '20: -498.6K Q1 '21: -480.4K Q2 '21: -1M Q3 '21: -523.7K Q4 '21: -1.2M Q1 '22: -1.5M Q2 '22: -878.3K Q3 '22: -890.4K Q4 '22: -1.4M Q1 '23: -666.7K Q2 '23: -925.3K Q3 '23: -601.4K Q4 '23: -718.1K Q1 '24: -1.2M Q2 '24: -1.4M Q3 '24: -1.7M Q4 '24: -1.7M Q1 '25: -324.4K Q2 '25: -582.4K Q3 '25: -850.3K Q4 '25: -1.4M Q1 '26: -5.1M Q2 '26: -869.5K Q3 '26: 2.2M Q4 '26: 5.1M Q1 '27: -963.6K Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q2 '23 Q3 '24 Q4 '25 Q1 '27

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-1.8M -1.2M -600K 0 600K 1.2M 1.8M Q2 '17: -296.1K Q3 '17: -341.8K Q4 '17: -357.4K Q1 '18: -246.9K Q2 '18: -358.8K Q3 '18: -417K Q4 '18: -259K Q1 '19: -344.8K Q2 '19: -159.6K Q3 '19: -307.8K Q4 '19: -196K Q1 '20: -80.8K Q2 '20: -61.8K Q3 '20: -149.4K Q4 '20: -364.4K Q1 '21: -145.7K Q2 '21: -517.8K Q3 '21: -320.9K Q4 '21: -607.7K Q1 '22: -710.4K Q2 '22: -1.1M Q3 '22: -405.1K Q4 '22: -430.6K Q1 '23: -847.1K Q2 '23: -535.2K Q3 '23: -180.9K Q4 '23: -371.8K Q1 '24: -1.5M Q2 '24: -655.8K Q3 '24: -1.1M Q4 '24: -1.7M Q1 '25: -246.4K Q2 '25: -317.4K Q3 '25: -353.6K Q4 '25: -1.1M Q1 '26: -1.8M Q2 '26: -811.5K Q3 '26: -509.7K Q4 '26: 265.5K Q1 '27: -944.3K Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q2 '23 Q3 '24 Q4 '25 Q1 '27

Free Cash Flow Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q2 '11: -3.4M Q2 '12: -294K Q2 '14: -437K Q3 '14: -151K Q4 '14: -116K Q1 '15: -87K Q2 '15: -80K Q3 '15: -111K Q4 '15: -10K Q1 '16: -58.5K Q3 '24: -1.2M Q2 '11 Q2 '14 Q4 '14 Q2 '15 Q4 '15 Q3 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 150M 300M 450M Q1 '11: 5.2M Q2 '11: 5.2M Q1 '12: 6.3M Q2 '12: 6.3M Q2 '14: 400M Q3 '14: 400M Q4 '14: 400M Q2 '15: 400M Q3 '15: 400M Q4 '15: 400M Q4 '21: 10.5M Q1 '22: 14.5M Q2 '22: 16.5M Q4 '22: 4.3M Q1 '23: 4.3M Q2 '23: 4.3M Q4 '23: 4.3M Q1 '24: 4.3M Q2 '24: 4.3M Q4 '24: 316.8K Q1 '25: 5.4M Q2 '25: 5.4M Q3 '25: 5.4M Q4 '25: 523.2K Q1 '26: 3.7M Q2 '26: 1.8M Q3 '26: 1.9M Q1 '27: 1.8M Q2 '12 Q2 '15 Q1 '22 Q2 '23 Q4 '24 Q4 '25 Q1 '27

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-60.00 -40.00 -20.00 0.00 20.00 40.00 60.00 Q2 '16: -0.09 Q3 '16: -0.09 Q4 '16: -52.92 Q1 '17: -52.98 Q2 '17: -52.97 Q3 '18: -0.21 Q4 '18: -0.21 Q1 '19: -0.24 Q2 '19: -0.25 Q3 '19: -0.26 Q4 '19: -0.26 Q1 '20: -0.22 Q2 '20: -0.18 Q3 '20: -0.17 Q4 '20: -0.16 Q1 '21: -0.19 Q2 '21: -0.28 Q3 '21: -0.26 Q4 '21: -0.32 Q1 '22: -0.37 Q2 '22: -0.32 Q3 '22: -0.32 Q4 '22: -0.53 Q1 '23: -0.57 Q2 '23: -0.73 Q3 '23: -0.82 Q4 '23: -0.67 Q1 '24: -0.80 Q2 '24: -0.91 Q3 '24: -1.15 Q4 '24: -6.42 Q1 '25: -6.20 Q2 '25: -5.99 Q3 '25: -5.77 Q4 '25: -3.08 Q1 '26: -4.39 Q2 '26: -4.75 Q3 '26: -3.45 Q4 '26: 0.59 Q1 '27: 1.43 Q2 '17 Q3 '19 Q4 '20 Q1 '22 Q2 '23 Q3 '24 Q4 '25 Q1 '27

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.